Medical device maker Medtronic to buy Covidien for $42.9 bn

June 16, 2014

US medical-device maker Medtronic will buy its Irish-based competitor Covidien for $42.9 billion, the company said late Sunday.

The deal would allow Medtronic to take advantage of Ireland's lower business tax rates—12.5 percent versus 35 percent in the United States.

The cash-and-stock transaction is valued at $93.22 per Covidien share, or some $42.9 billion based on Medtronic's closing stock price of $60.70 per share on June 13, the statement read.

The combined company will have a broad product portfolio and some 87,000 employees in more than 150 countries.

Once the transaction is complete, "the businesses of Medtronic and Covidien will be combined under a new entity to be called Medtronic plc," the statement read.

"It will have its principal executive offices in Ireland, where Covidien's current headquarters resides and where both companies have a longstanding presence."

Medtronic plc however will continue to have its operational headquarters in Minneapolis, Minnesota, where the company currently employs more than 8,000 people.

"This acquisition will allow Medtronic to reach more patients, in more ways and in more places," said Medtronic Chairman and Chief Executive Officer Omar Ishrak.

Medtronic produces orthopedic and cardiovascular devices and is valued at around $61 billion, against $32 billion for Covidien, which focuses on devices used for surgery.

A number of US companies, in particular in the pharmaceutical industry, have recently launched bids to buy companies as a way to reduce their costs and tax burden and use their cash overseas.

Pfizer recently abandoned an attempt to buy British firm AstraZeneca for $117 billion in a deal that would have allowed the US company to take advantage of Britain's lower corporate tax rate.

The United States is considering amending its legislation to allow multinational companies to keep overseas indefinitely a portion of their profits in order to avoid paying US taxes on it.

Explore further: Medical-device maker Medtronic in talks to buy Irish rival

Related Stories

Mallinckrodt buying Questcor for about $5.6B (Update)

April 7, 2014

Mallinckrodt is buying California-based Questcor Pharmaceuticals Inc. for a combination of stock and cash valued at about $5.6 billion that will help to further diversify the Irish company's business.

Recommended for you

Your (social media) votes matter

January 24, 2017

When Tim Weninger conducted two large-scale experiments on Reddit - otherwise known as "the front page of the internet" - back in 2014, the goal was to better understand the ripple effects of malicious voting behavior and ...

Protective wear inspired by fish scales

January 24, 2017

They started with striped bass. Over a two-year period the researchers went through about 50 bass, puncturing or fracturing hundreds of fish scales under the microscope, to try to understand their properties and mechanics ...

'Droneboarding' takes off in Latvia

January 22, 2017

Skirted on all sides by snow-clad pine forests, Latvia's remote Lake Ninieris would be the perfect picture of winter tranquility—were it not for the huge drone buzzing like a swarm of angry bees as it zooms above the solid ...

Singapore 2G switchoff highlights digital divide

January 22, 2017

When Singapore pulls the plug on its 2G mobile phone network this year, thousands of people could be stuck without a signal—digital have-nots left behind by the relentless march of technology.

Making AI systems that see the world as humans do

January 19, 2017

A Northwestern University team developed a new computational model that performs at human levels on a standard intelligence test. This work is an important step toward making artificial intelligence systems that see and understand ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.